In this review, the roles of Fc-gamma receptor polymorphisms are discussed in regards to HIV-1 vaccine efficacy, HIV acquisition, and disease progression. In addition, the significance of the neonatal immunoglobulin G (IgG) Fc receptor and potential effects of the aggregated immunoglobulin A Fc receptor (FcalphaR) are addressed.
INTRODUCTION
In the seminal study by Hessel et al. [1] in 2007, the role of Fc receptors (FcR) for HIV-specific antibody function was demonstrated in the nonhuman primate (NHP) model. This study showed a dramatic decrease in the protection afforded by broadly neutralizing antibodies when the Fc-binding activity was engineered out. In addition, a recent study using mice-expressing human Fc-gamma-Rs has also shown that broadly neutralizing hemagglutinin stalk-specific antibodies require interaction with activating Fc-gamma-Rs to provide protection against influenza [2 & ]. Furthermore, the RV144 clinical trial in Thailand, which showed a modest protective effect, demonstrated that in the presence of low levels of HIV-specific plasma immunoglobulin A (IgA), non-neutralizing immunoglobulin G (IgG)-binding antibodies capable of antibodydependent cellular cytotoxicity (ADCC) were associated with a decreased risk of infection [3, 4] . The function of FcR is, however, dependent on polymorphic allelic forms of these receptors. The importance of FcR polymorphisms in clinical outcome has been extensively documented in oncology wherein an increased relative affinity of the polymorphic Fc receptor allelic forms resulted in a more efficient immunologic control of cancers [5 & ]. In this review, we will summarize the role of Fc-gamma receptor (Fc-gamma-R) polymorphisms in vaccine efficacy and HIV acquisition/infection and disease
Fc RECEPTORS
Antibodies mediate some of their effector activities via their Fc domains attaching to cellular receptors. Each subclass of antibody/immunoglobulin binds to different classes of receptors.
Fc-gamma receptors
Fc-gamma receptors (Fc-gamma-R) are the cellular receptors, which bind the crystallizable fragment or Fc region of immunoglobulin G (IgG) subtype antibodies, that is the base portion of the 'Y'-shaped immunoglobulin monomer. FcRs can be divided into two main types: activating and inhibitory. There are six different types of Fc-gamma-R: Fc-gamma-RI (CD64), Fc-gamma-RIIA (CD32A), Fc-gamma-RIIC (CD32C), Fc-gamma-RIIIA (CD16A), Fc-gamma-RIIIB (CD16B), which are all activating receptors, and Fc-gamma-RIIB (CD32B), the only inhibitory receptor [6] . The activating receptors, with the exception of Fc-gamma-RIIA, require association with a separate signaling protein, the gamma-chain, in order for cell signaling to occur [7] . Fc-gamma-RIIA and Fc-gamma-RIIB have intrinsic signaling motifs, immunoreceptor tyrosine-based activation motif (ITAM), or immunoreceptor tyrosine-based inhibition motif (ITIM), respectively within their cytoplasmic tails. Fc-gamma-Rs are expressed on most cells of the innate immune system (monocytes, macrophages, natural killer (NK) cells, neutrophils, and others) and on B cells, but not on T cells. NK cells typically express Fc-gamma-RIIIA and in some individuals Fc-gamma-RIIC [8, 9] . Fc-gamma-RIIB is predominantly expressed on neutrophils, eosinophils, and B cells. Fc-gamma-RIIA is the most widely expressed Fc-gamma-R and is usually co-expressed with Fc-gamma-RIIB, as this receptor regulates the immune response [10] . Fc-gamma-RIIA and Fc-gamma-RIIIA retain low affinity for monomeric IgG and preferentially bind to immune complexes [10] . Fc-gamma-RIIA and Fc-gamma-RIIIA retain low affinity for monomeric IgG and preferentially bind to immune complexes [10] . Fc-gamma-RI is the only high-affinity Fc-gamma-R in that it can bind both monomeric antibodies and immunecomplexes. Upon ligation of the receptors with immune complexes, several effector functions can be elicited, including ADCC, antibody-dependent cellular phagocytosis (ADCP), and antibody-dependent cell-mediated virus inhibition (ADCVI).
Fc-gamma receptor single nucleotide polymorphisms
Allelic variations in the form of a single nucleotide polymorphism (SNP) occur in Fc-gamma-RIIA and Fc-gamma-RIIIA, at positions 131 and 158, respectively. Human Fc-gamma-RI is not polymorphic. These SNPs attain clinical and functional relevance, effecting IgG binding, immune effector functions, and responsiveness to biological medicines [11] . Fc-gamma-RIIA has a polymorphic residue at position 131, either a histidine or an arginine (H131R). The presence of at least one histidine allele is required for binding to IgG2, and binding to IgG1 and IgG3 is higher compared with binding to receptors with an arginine allele [12] . Fc-gamma-RIIIA has a SNP at position 158 resulting in either a phenylalanine (F) or valine (V). The valine allele has a greater affinity for IgG than the phenylalanine allele, which has clinical implications in the monoclonal antibody therapy for B-cell lymphoma and other cancers [5 & ]. The pathogenesis of infectious diseases can be modulated by these allelic variants. HIV disease progression, risk of infection, and vaccine efficacy have been shown to be affected by these polymorphisms [13] . However, some study results appear contradictory or not replicated in various patient cohorts.
Fc-gamma-RIIA and HIV
Several studies have investigated the role of the Fc-gamma-RIIA polymorphism in HIV infection, acquisition after vaccination, or disease progression. Fc-gamma-RIIA genotype has been demonstrated to predict progression of HIV infection. Specifically, patients homozygous for the low-binding allele,
KEY POINTS
Fc receptors play an important role in antibodymediated action of HIV-specific antibodies.
As a consequence of the importance of Fc receptors in HIV antibody function, polymorphic allelic forms of Fc-gamma-RIIA and Fc-gamma-RIIIA with a higher affinity 'should' be associated with a more benign disease course of HIV infection and/or more efficient vaccine protection. However, a conclusive result as to the relative role of polymorphic allelic variants of these receptors is still elusive.
Recent observations have shown that the neonatal immunoglobulin G (IgG) Fc receptor may enhance HIV-1 transcytosis across epithelial cells.
homozygous arginine 131, progressed to a CD4 þ cell count of less than 200 cells/mm 3 more rapidly than individuals homozygous for the high-binding allele, homozygous histidine 131 (HH131), or heterozygous for the two alleles arginine/histidine 131 (RH131). However, the same study also showed that individuals with the homozygous histidine 131 (HH131) genotype were more likely to develop Pneumocystis jiroveci pneumonia as the AIDS-defining opportunistic disease [14] . Likewise, the homozygous histidine 131 (HH131) genotype has been associated with increased risk of placental malaria in HIV-infected women [15] and with other perinatal infections [16] .
The presence of the histidine allele, either in the heterozygous arginine/histidine (RH131) or homozygous histidine (HH131) version, was associated with lower HIV replication in patients who mounted a robust anti-p24 IgG2 response after vaccination with a highly attenuated recombinant fowlpox virus vector-expressing HIV Gag-Pol and interferon-gamma (IFN-gamma) [17] . Moreover, individuals with the homozygous histidine 131 (HH131) genotype exhibited the highest ADCVI responses after vaccination with recombinant gp120 protein. The effect of the histidine allele was dose dependent, with arginine/histidine131 (RH131) having intermediate and arginine/arginine 131 (RR131), the lowest ADCVI activity [18] . In contrast, other studies, including the RV144 trial and VAX004 trials have not found an association of this allele with HIV infection or response to vaccination (poster 420, Kijak et al., CROI 2012 and [19] ).
Fc-gamma-RIIIA and HIV-1
There is still some uncertainty regarding the role of Fc-gamma-RIIIA in HIV-1 infection, disease progression, and vaccination. Valine 158 phenylalanine (V158F) polymorphism, which is caused by different isoforms with either a valine (V) or a phenylalanine (F) in amino acid position 158 of Fc-gamma-RIIIA, results in different binding affinity to IgG1 and IgG3. Forthal et al. [14] showed no effect of valine/phenylalanine (V158F) polymorphism on HIV-1 disease progression in infected individuals in the Multicenter AIDS Cohort Study. However, they recapitulated findings of an association of valine/ phenylalanine (V158F) gene polymorphism and the development of Kaposi's sarcoma as the AIDSdefining illness [14, 20] . In contrast, Poonia et al. [21] showed that the homozygous valine 158 Fc-gamma-RIIIA genotype was associated with a higher rate of HIV disease progression. Although homozygous valine 158 (VV158) individuals were predominantly in the HIV progressor group, higher frequencies of the valine158 allele were also detected among all HIV-infected patients compared with natural virus suppressors and uninfected controls. Conversely, the combination of homozygous phenylalanine158 Fc-gamma-RIIIA and homozygous arginine 131 Fc-gamma-RIIIA, that is double homozygosity for low activity alleles was associated with HIV disease progression [22] .
Valine158 [19] . Testifying to the complicated nature of Fc receptor and immune-related gene loci attributing to HIV infection risk after vaccination, another analysis found no association between the histidine/arginine131 Fc-gamma-RIIA or phenylalanine/valine 158 Fc-gamma-RIIIA variants alone and risk of infection. However, when analyzed in combination with the genetic markers of immunoglobulin gamma and kappa-type light chains, GM and KM respectively, an association was noted between the immunoglobulin gamma-type light chain 23 þ/-(GM23 þ/-) allele and the high affinity valine158 allele. An association was lacking for immunoglobulin gamma-type light chain (GM) or immunoglobulin kappa-type light chain (KM) alleles alone and immunoglobulin kappa-type light chain /Fc receptor combinations [22] . Extensive analysis of the RV144 trial, revealed that the vaccine more efficiently protected individuals with the homozygous phenylalanine158 genotype in regards to disease progression to a CD4 þ T-cell count of less than 350 cells/microliter, time to highly active antiretroviral therapy initiation, or AIDS-defining illnesses. These modulatory effects were only significant in men (Poster 420, Kijak et al., CROI 2012). This sex bias observation correlates with the previous study showing an effect of the Fc-gamma-RIIIA genotype on vaccination, compared with studies, which could not replicate the effect, as the VAX004 trial was a male only cohort. Therefore, these studies point to risks with both the low-binding and highbinding alleles, depending on what other genetic factors and endpoints are considered.
NEONATAL IMMUNOGLOBULIN G Fc RECEPTOR IN VACCINATION AND INFECTION
The neonatal IgG Fc receptor (FcRn) is a major histocompatibility complex class I-like heterodimer composed of the ligand-binding alpha-chain noncovalently associated to beta-2-microglobulin, the signaling domain [23, 24] . It is expressed in a variety of cells and tissues, including the mucosal epithelial cell barriers in the intestine, the lung, and at the maternal-fetal barrier of the placental mucosal epithelium [25] . In early life, FcRn provides passive immunity to the fetus in utero via transfer of maternal IgG [26] . In adults, its function is to transport IgG across polarized epithelial cells and to rescue IgG and albumin from lysosomal degradation, contributing to the long plasma half-life of these proteins [27] . A unique feature of FcRn is the pH-dependent binding [28] . IgG is internalized into early endosomes, acidic intracellular compartments, in which FcRn binds to the Fc region of IgG. The FcRn-IgG complexes are transported from the apical cell membrane via recycling endosomes that bud and mature into secretory vesicles to the opposite basolateral side of the cell wherein FcRn releases IgG, mediated by the neutral pH at the plasma membrane [29] .
As the neonatal IgG Fc receptor (FcRn) transports IgG in mucosal epithelia, fusion proteins were engineered to target antigens at mucosal surfaces, allowing transcytosis to the antigen-presenting cells on the other side. Fusion proteins of HIV-Gag (p24) to the Fc region of IgG in the presence of the adjuvant CpG were administered to mice intranasally. This immunization regimen resulted in local and systemic immunity, including Gagspecific antibody responses in serum and at mucosal sites. In addition, durable memory responses were induced, such as antibody secreting plasma cells and IFN-gamma-producing T cells that provided protection against challenge with a recombinant vaccinia virus-expressing HIV Gag protein [30] .
FcRn has been attributed to facilitating sexual transmission of HIV-1 by enhancing transcytosis across cervico-vaginal, penile urethra, and intestinal epithelia. Anti-HIV-1-specific-IgG-complexed HIV-1 isolates showed enhanced transcytosis, augmented by the acidic pH of cervico-vaginal or seminal fluids, facilitating viral transmission to susceptible target cells in the mucosal tissue. The transcytosis was abrogated in FcRn-knockdown cells or when FcRn-IgG interaction was blocked. Strong binding antibodies resulted in a more FcRn-dependent transcytosis rendering the virus more infectious, whereas strong neutralizing antibodies reduced the infectivity of the transcytosed virus [31 & ]. These investigations raise questions whether nonneutralizing, binding antibodies are at all beneficial for containment of viral spread, which is an issue that requires further exploration utilizing animal models.
Fc-alpha-R and HIV
The role of IgA antibodies in HIV-1 vaccines remains subject to debate. The RV144 clinical trial indicated that augmented HIV-Env-specific serum IgA levels correlated with decreased protection efficacy; however, mucosal IgA was not measured [3] . In a recent DNA-based vaccine study aimed at elucidating the role of mucosal IgA in vaccine efficacy, macaques receiving an additional mucosal adjuvant had a protection rate of 80% compared with 60% with the DNA vaccine only. Protected monkeys had increased levels of vaginal IgA, but a correlation with serum IgA was lacking. The greatest viremic control was achieved in monkeys with the highest levels of vaginal IgG and IgA. The authors concluded that vaginal IgA is protective against mucosal transmission, and that mucosal sampling should be included in future clinical studies (oral abstract OA04.02, Hutnick et al., AIDS Vaccine 2013). In light of these findings, a deeper understanding of the receptors for IgA is warranted in both humans and macaques. Fc-alpha-R has been shown to alternatively spliced in both humans and macaques, with 10 and six splice variants reported, respectively. In addition, a SNP is present in the cytoplasmic domain of human Fc-alpha-R (also known as CD89), resulting in either serine or glycine at position 248 (S248G). These alleles differ significantly in calcium mobilization, degrantenulation, and cytokine release. The glycine248 (G248) allele mediates interleukin-6 release independently of FcR gamma-chain association, whereas the serine 248 (S248) allele cannot. Similar to some Fc-gamma-R allelic forms, the Glycine 248 allele occurs enriched in systemic lupus erythematosus populations, and therefore may contribute to the proinflammatory potential of IgA [32] . The role of Fc-alpha-R in HIV-1 infection and vaccination remains unclear. Future studies may help examine whether Fc-alpha-R is polymorphic in widely used NHP models and elucidate its role in HIV/simian immunodeficiency virus (SIV) infection and vaccines.
NONHUMAN PRIMATE STUDIES OF Fc RECEPTORS
NHP, such as rhesus, pig-tailed, and cynomolgus macaques are widely used in the preclinical evaluation of monoclonal antibodies and vaccine candidates. As NHP can be infected with pathogenic SIV, the simian equivalent for HIV, the SIV/NHP animal model is one of the most important research tools in the quest for an effective HIV-1 vaccine. As the effector functions of antibodies are mediated by FcRs, the sequence and function of the receptors in NHP are of crucial importance to translate into optimized vaccine design by addressing efficient antibody production and function. Fc-gamma-R in rhesus macaques is highly polymorphic, with three Fc-gamma-RI, five Fc-gamma-RIIA, and three Fc-gamma-RIIIA allelic variants being described in a small cohort of nine animals [33] . Another study identified different Fc-gamma-RIIIA allelic variants in rhesus macaques. These allelic variants resulted in different outcomes after administration of an anti-CD20 antibody [34] . Sequences obtained from pigtailed macaques confirmed a high degree of polymorphism in Fc-gamma-RIIA, with eight distinct allelic variants identified [35] . These studies indicate that a more thorough investigation of the full range of FcR in different NHP species, utilizing larger cohorts from several breeding colonies, is warranted for a more accurate interpretation of vaccine and therapeutic antibody studies in NHP models.
As NHPs are extensively used to study an AIDSlike disease in an animal model and/or serve as study subjects in preclinical AIDS vaccine trials, the diversity and function of FcRs are currently being extensively investigated in a number of laboratories, including our own. In light of the difficulty in eliciting broadly neutralizing antibodies, multiple laboratories are investigating the efficacy of antibodies that are specifically designed either in regards to their immunoglobulin class and/or their relative activity of the Fc domain and the antibody glycosylation pattern [36] . Passive immunization strategies in NHPs are extensively performed to determine which characteristics of antibodies may yield the best possible outcome in low-dose AIDS virus challenge studies [37 & ].
CONCLUSION
Although the clinical advantage of relative high affinity polymorphic forms of FcR has been extensively documented in oncology, the functions of these receptors appear to be by far more complex in HIV-infected individuals and vaccine trials. Reasons for this heterogenic outcome are likely multifarious; it is conceivable that the number of individuals investigated is still too low to determine a definitive conclusion. In addition, the particular circumstances of HIV-infected individuals or vaccinees may significantly influence whether the overall impact of the polymorphisms is more beneficial or not. Although a relatively higher affinity will result in an increased efficacy, this could also mean that the overall immune activation is increased, which is not necessarily beneficial in HIV infection. A further complication is the observation that certain bacterial, viral, and parasitic protozoal infectious agents may benefit from higher affinity polymorphic Fc receptors, and thus an increased pathogenicity may be observed in humans [14, 15, 20, 38] .
More detailed investigations are needed to fully appreciate the overall role of Fc receptors in HIV pathogenesis in humans and NHPs. The ultimate goal should be to determine how this knowledge can be harnessed for optimal design of an effective HIV vaccine.
